Cancer
Conditions
Keywords
circulating tumor cells (CTCs), CTC clusters, Molecular analysis of CTCs, CTC culture, overall survival (OS), progression free survival (PFS)
Brief summary
This observational study with circulating tumor cells (CTC) count, isolation and analysis at several time points during disease progression is to investigate the role and biology of CTCs and clusters of CTCs in different cancer types. It also evaluates the role of CTCs as biomarkers, and aims at the identification of key signaling networks that are active in CTCs.
Interventions
OTHERBlood samples
Blood samples (3 ethylenediaminetetraacetic acid (EDTA) tubes with a volume of 7.5 ml blood each) will be processed for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen.
OTHERSamples from tumor draining vessels
In case of tumor resection, 3 EDTA tubes (5 ml) will be withdrawn from the tumor draining vessels for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen.
Sponsors
University Hospital, Basel, Switzerland
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult cancer patients * All patients with histology-based proved diagnosis of cancer, all stages and subtypes can be included. Precancerous lesions cannot be included. * All patients with the diagnosis of a solid tumor including adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma, sarcoma * Written pathology report must be available. * Written informed consent.
Exclusion criteria
* No written informed consent. * No proved diagnosis of malignancy by pathology report. * Patients with the diagnosis of blood cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) in heterogeneous cancer population | Screening (Visit 1) until the date of death (assessed up to 240 months) | overall survival (OS) in heterogeneous cancer population |
| Change in total number of isolated CTCs | Through study completion, an average of 20 years | Change in total number of isolated CTCs |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival (PFS) | Through study completion, an average of 20 years | progression free survival (PFS) in the different cancer cohorts with different treatment regimes |
Other
| Measure | Time frame | Description |
|---|---|---|
| Change in circulating tumor DNA (ctDNA) from blood samples | Through study completion, an average of 20 years | Change in circulating tumor DNA (ctDNA) from blood samples |
Countries
Switzerland
Contacts
Primary ContactMarcus Vetter, PD Dr. med.
Backup ContactNicola Aceto, Prof. Dr. med.
Outcome results
None listed